Bruno Podesser

SGV Meeting 2026 · Scientific Programme

CHUV, Lausanne

• 24 November 2026 · 09:15Large animal models in translational cardiovascular research
  Abstract

  The continuous demand for innovation in science and industry drives the development of novel compounds and medical devices. This process operates within a tightly regulated framework that is itself subject to constant adaptation. In Europe, the introduction of the Medical Device Regulation (MDR) has transformed the device landscape, with initiatives such as the breakthrough medical device (BtMD) designation further redefining regulatory pathways. Similar dynamics apply to the development and testing of new drugs and in vitro diagnostics (IVD)’s.

  This presentation will outline the importance of understanding physiology in the era of -omics technologies and artificial intelligence. I will highlight that the “pipeline of innovation” is depending on permeability in order to allow new ideas and scientific developments to become novel therapies and innovative devices. Besides the scientific part of the pipeline, I will also address the regulatory framework required to bring new drugs or devices to the market. I will briefly address human-relevant models beyond traditional rodent and canine studies, with a particular focus on in silico and in vitro approaches, including high-throughput iPSC-based organoid systems. For medical devices, we will examine available small and large animal models used to evaluate biocompatibility and functional performance of implantable technologies. Finally, a case study will illustrate the journey of a Class III medical device—from initial concept through patenting to prototype development.

  By the conclusion of this presentation, participants should understand the importance of physiology in large animals as one aspect in the evaluation of innovative medical products.